Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma

References

• Ekenel M, Deangelis LM. Treatment of primary Central nervous system lymphoma. Curr Treat Options Neurol. 2007;9(4):271–282. doi: 10.1007/s11940-007-0013-6.
   PubMedGoogle Scholar
• Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol. 2009;8(6):581–592. doi: 10.1016/S1474-4422(09)70091-2.
   PubMed Web of Science ®Google Scholar
• Deangelis LM, Iwamoto FM. An update on therapy of primary Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program. 2006;2006(1):311–316. doi: 10.1182/asheducation-2006.1.311.
   Google Scholar
• Grier J, Batchelor T. Metastatic neurologic complications of non-Hodgkin’s lymphoma. Curr Oncol Rep. 2005;7(1):55–60. doi: 10.1007/s11912-005-0026-9.
   PubMedGoogle Scholar
• Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011;118(3):510–522. doi: 10.1182/blood-2011-03-321349.
   PubMed Web of Science ®Google Scholar
• Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24(28):4570–4574. doi: 10.1200/JCO.2006.06.6910.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511. doi: 10.1038/35000501.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92. doi: 10.1038/nature08638.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–119. doi: 10.1038/nature09671.
   PubMed Web of Science ®Google Scholar
• Kloo B, Nagel D, Pfeifer M, et al. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2011;108(1):272–277. doi: 10.1073/pnas.1008969108.
   PubMed Web of Science ®Google Scholar
• Camilleri-Broët S, Crinière E, Broët P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190–196. doi: 10.1182/blood-2005-03-1024.
   PubMed Web of Science ®Google Scholar
• Korfel A, Schlegel U, Herrlinger U, et al. Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma. J Clin Oncol. 2016;34(15):1757–1763. doi: 10.1200/JCO.2015.64.9897.
   PubMedGoogle Scholar
• Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282–290. doi: 10.1200/JCO.2011.36.1360.
   PubMed Web of Science ®Google Scholar
• Maira S-M, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11(2):317–328. doi: 10.1158/1535-7163.MCT-11-0474.
   PubMed Web of Science ®Google Scholar
• Cho C-F, Wolfe JM, Fadzen CM, et al. Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents. Nat Commun. 2017;8:15623. doi: 10.1038/ncomms15623.
   PubMed Web of Science ®Google Scholar
• de Gooijer MC, Zhang P, Buil LCM, et al. Buparlisib is a brain penetrable pan-PI3K inhibitor. Sci Rep. 2018;8(1):10784. doi: 10.1038/s41598-018-29062-w.
   PubMedGoogle Scholar
• Wen PY, Touat M, Alexander BM, et al. Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial. J Clin Oncol. 2019;37(9):741–750. doi: 10.1200/JCO.18.01207.
   PubMed Web of Science ®Google Scholar
• van den Bent M, Azaro A, De Vos F, et al. A phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol. 2020;146(1):79–89. doi: 10.1007/s11060-019-03337-2.
   PubMed Web of Science ®Google Scholar
• Cheng DT, Mitchell TN, Zehir A, et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251–264. doi: 10.1016/j.jmoldx.2014.12.006.
   PubMed Web of Science ®Google Scholar
• Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–1029. doi: 10.1158/2159-8290.CD-17-0613.
   PubMed Web of Science ®Google Scholar
• Grommes C, Stone J, Nolan C, et al. Phase 1B of ibrutinib and high-dose methotrexate for recurrent/refractory CNS lymphoma. J Clin Oncol. 2017;35(15_suppl):7533–7533. doi: 10.1200/JCO.2017.35.15_suppl.7533.
   Google Scholar
• Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–219. doi: 10.1038/nbt.2514.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi: 10.1182/blood-2003-05-1545.
   PubMed Web of Science ®Google Scholar
• Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of Central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal Central nervous system prophylaxis: a GELA study on 974 patients. Groupe d‘Etudes des lymphomes de l‘Adulte. Ann Oncol. 2000;11(6):685–690. doi: 10.1023/a:1008394827806.
   PubMed Web of Science ®Google Scholar
• Tyson RM, Siegal T, Doolittle ND, et al. Current status and future of relapsed primary Central nervous system lymphoma (PCNSL). Leuk Lymphoma. 2003;44(4):627–633. doi: 10.1080/1042819021000055057.
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, López-Guillermo A, Bessell EM, et al. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary Central nervous system lymphoma. Eur J Haematol. 2003;70(4):219–224. doi: 10.1034/j.1600-0609.2003.00045.x.
   PubMed Web of Science ®Google Scholar
• Enting RH, Demopoulos A, DeAngelis LM, et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004;63(5):901–903. doi: 10.1212/01.wnl.0000137050.43114.42.
   PubMed Web of Science ®Google Scholar
• Fischer L, Thiel E, Klasen H-A, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006;17(7):1141–1145. doi: 10.1093/annonc/mdl070.
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Rademaker A, Evens AM, et al. Pemetrexed in the treatment of relapsed/refractory primary Central nervous system lymphoma. Cancer. 2012;118(15):3743–3748. doi: 10.1002/cncr.26709.
   PubMed Web of Science ®Google Scholar
• Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007;96(6):864–867. doi: 10.1038/sj.bjc.6603660.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Grossman SA, Mikkelsen T, et al. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76(10):929–930. doi: 10.1212/WNL.0b013e31820f2d94.
   PubMed Web of Science ®Google Scholar
• Heffron TP, Ndubaku CO, Salphati L, et al. Discovery of clinical development candidate GDC-0084, a brain penetrant inhibitor of PI3K and mTOR. ACS Med Chem Lett. 2016;7(4):351–356. doi: 10.1021/acsmedchemlett.6b00005.
   PubMed Web of Science ®Google Scholar